No Data
No Data
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan
Shenzhen Neptunus Bioengineering (SHE:000078), through its subsidiary Shandong Neptune Galaxy Pharmaceutical, will build the first phase of a smart logistics park for 298 million yuan, according to th
Express News | Haiwang Biotech invests in the establishment of an agricultural technology company with chemical fertilizer sales business
Haiwang Biotech (000078.SZ): It has now built a diversified, multi-level pharmaceutical product structure
Gelonghui, Feb. 5 | Haiwang Biotech (000078.SZ) said on the investor interactive platform that the company's pharmaceutical industry sector is mainly engaged in drug R&D, production and sales, with subsidiaries Haiwangfu Pharmaceutical, Jinxiang Traditional Chinese Medicine and Haiwang Zhongxin Pharmaceutical as the main platforms. The company has now built a diversified and multi-level pharmaceutical product structure. Haiwang Pharmaceutical's main business is R&D, production and sales of large infusion products, Western medicine preparations, etc.; Jinxiang Traditional Chinese Medicine is a medium-sized traditional Chinese medicine manufacturer and sales enterprise in Fujian Province, responsible for R&D, production and sales of proprietary Chinese medicines; Haiwang Zhongxin Pharmaceutical is a company integrating R&D, production and sales of pharmaceutical products
Express News | More than 10 listed companies announced additional shareholders' pledges after the market, 20 companies interacted easily to respond to whether there is a risk of stock pledges
Haiwang Biotech: Controlling shareholder plans to transfer 10% of the company's shares to Silk Spinning Group
Gelonghui, January 14 | Neptune Biotech announced that Haiwang Group, the controlling shareholder of the company, plans to transfer some of its shares to Guangdong Silk Textile Group Co., Ltd. (“Silk Spinning Group”), totaling 275 million shares, accounting for 10% of the company's total share capital. The proposed transfer price for each share of the underlying shares is 3.13 yuan/share, and the final price will be confirmed in the form of a formal share transfer agreement. After the implementation of this transaction is completed, it will help the company to use the strong strength of state-owned capital to continuously improve its industrial structure and further enhance its market competitiveness.
Neptune Biotech (000078.SZ): NEP018 of NEP018 of NEP018 from NEP018 was approved by the US FDA to enter human clinical trials
Gelonghui, December 29丨Haiwang Biotech (000078.SZ) announced that the company's wholly-owned subsidiary Shenzhen Haiwang Pharmaceutical Technology Research Institute Co., Ltd. (“Haiwang Pharmaceutical Research Institute”) recently received a written notice from the US Food and Drug Administration to approve NEP018, a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and with independent intellectual property rights, to carry out human clinical trials of phase I drugs in the US. NEP018 is a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and has independent intellectual property rights. Comprehensive non-clinical study showed that NEP018 was effective against VEGF
No Data